Phathom Pharmaceuticals Stock Price To Earning

PHAT Stock

USD 8.87 0.10 1.11%

Phathom Pharmaceuticals fundamentals help investors to digest information that contributes to Phathom Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Phathom Stock. The fundamental analysis module provides a way to measure Phathom Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Phathom Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Phathom Pharmaceuticals Company Price To Earning Analysis

Phathom Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Phathom Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Phathom Pharmaceuticals is extremely important. It helps to project a fair market value of Phathom Stock properly, considering its historical fundamentals such as Price To Earning. Since Phathom Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Phathom Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Phathom Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Long Term Debt	Long Term Debt Total	Common Stock	Property Plant Equipment	Net Receivables
Total Assets		0.25	0.26	0.86	-0.95	-0.87	0.84	0.94	0.77	0.74	0.94	1.0	1.0	0.07	0.77	0.72	0.85	0.71	0.62
Total Stockholder Equity	0.25		1.0	-0.03	-0.36	0.18	0.09	0.22	-0.38	0.8	0.31	0.26	0.27	0.43	-0.35	-0.27	-0.25	-0.18	-0.41
Net Tangible Assets	0.26	1.0		-0.02	-0.38	0.17	0.1	0.23	-0.36	0.81	0.32	0.28	0.29	0.42	-0.34	-0.26	-0.24	-0.17	-0.39
Current Deferred Revenue	0.86	-0.03	-0.02		-0.78	-0.96	0.9	0.93	0.85	0.55	0.87	0.86	0.84	0.1	0.88	0.87	0.87	0.7	0.59
Net Debt	-0.95	-0.36	-0.38	-0.78		0.78	-0.77	-0.85	-0.72	-0.81	-0.84	-0.96	-0.96	-0.14	-0.6	-0.52	-0.73	-0.63	-0.63
Retained Earnings	-0.87	0.18	0.17	-0.96	0.78		-0.8	-0.9	-0.94	-0.44	-0.84	-0.86	-0.86	0.14	-0.94	-0.89	-0.91	-0.72	-0.73
Accounts Payable	0.84	0.09	0.1	0.9	-0.77	-0.8		0.84	0.7	0.54	0.8	0.83	0.79	0.46	0.72	0.7	0.81	0.86	0.47
Capital Surpluse	0.94	0.22	0.23	0.93	-0.85	-0.9	0.84		0.72	0.73	0.99	0.94	0.93	0.05	0.82	0.83	0.8	0.66	0.45
Total Liab	0.77	-0.38	-0.36	0.85	-0.72	-0.94	0.7	0.72		0.24	0.64	0.76	0.75	-0.21	0.88	0.76	0.91	0.72	0.91
Net Invested Capital	0.74	0.8	0.81	0.55	-0.81	-0.44	0.54	0.73	0.24		0.76	0.75	0.75	0.29	0.24	0.27	0.32	0.22	0.11
Short Long Term Debt	0.94	0.31	0.32	0.87	-0.84	-0.84	0.8	0.99	0.64	0.76		0.94	0.94	0.05	0.76	0.79	0.75	0.63	0.37
Total Current Assets	1.0	0.26	0.28	0.86	-0.96	-0.86	0.83	0.94	0.76	0.75	0.94		1.0	0.08	0.76	0.72	0.85	0.71	0.61
Net Working Capital	1.0	0.27	0.29	0.84	-0.96	-0.86	0.79	0.93	0.75	0.75	0.94	1.0		0.02	0.75	0.71	0.83	0.67	0.61
Short Term Debt	0.07	0.43	0.42	0.1	-0.14	0.14	0.46	0.05	-0.21	0.29	0.05	0.08	0.02		-0.24	-0.19	-0.05	0.29	-0.27
Long Term Debt	0.77	-0.35	-0.34	0.88	-0.6	-0.94	0.72	0.82	0.88	0.24	0.76	0.76	0.75	-0.24		0.97	0.94	0.67	0.68
Long Term Debt Total	0.72	-0.27	-0.26	0.87	-0.52	-0.89	0.7	0.83	0.76	0.27	0.79	0.72	0.71	-0.19	0.97		0.87	0.61	0.49
Common Stock	0.85	-0.25	-0.24	0.87	-0.73	-0.91	0.81	0.8	0.91	0.32	0.75	0.85	0.83	-0.05	0.94	0.87		0.78	0.79
Property Plant Equipment	0.71	-0.18	-0.17	0.7	-0.63	-0.72	0.86	0.66	0.72	0.22	0.63	0.71	0.67	0.29	0.67	0.61	0.78		0.55
Net Receivables	0.62	-0.41	-0.39	0.59	-0.63	-0.73	0.47	0.45	0.91	0.11	0.37	0.61	0.61	-0.27	0.68	0.49	0.79	0.55

Click cells to compare fundamentals

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Competition

Predict Phathom Pharmaceuticals

Phathom Retained Earnings

Retained Earnings

(882.25 Million)

At this time, Phathom Pharmaceuticals' Retained Earnings are comparatively stable compared to the past year.

Based on the latest financial disclosure, Phathom Pharmaceuticals has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.0% higher than that of the company.

Phathom Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phathom Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phathom Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phathom Pharmaceuticals by comparing valuation metrics of similar companies.

Phathom Pharmaceuticals is currently under evaluation in price to earning category among its peers.

Phathom Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Phathom Pharmaceuticals from analyzing Phathom Pharmaceuticals' financial statements. These drivers represent accounts that assess Phathom Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Phathom Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	770.0M	1.1B	727.8M	438.9M	468.3M	682.0M
Enterprise Value	549.8M	865.4M	635.9M	380.6M	225.9M	214.6M

Phathom Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Phathom Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Phathom Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Phathom Fundamentals

	Return On Equity	-34.89
	Return On Asset	-0.58
	Operating Margin	(4.33) %
	Current Valuation	455.08 M
	Shares Outstanding	68.38 M
	Shares Owned By Insiders	7.69 %
	Shares Owned By Institutions	92.31 %
	Number Of Shares Shorted	14.66 M
	Price To Book	25.37 X
	Price To Sales	23.35 X
	Revenue	682 K
	EBITDA	(159.05 M)
	Net Income	(201.59 M)
	Cash And Equivalents	207.39 M
	Cash Per Share	5.39 X
	Total Debt	139.03 M
	Debt To Equity	2.43 %
	Current Ratio	9.93 X
	Book Value Per Share	(2.74) X
	Cash Flow From Operations	(137.58 M)
	Short Ratio	8.61 X
	Earnings Per Share	(5.74) X
	Target Price	25.29
	Number Of Employees	452
	Beta	0.72
	Market Capitalization	613.35 M
	Total Asset	413.84 M
	Retained Earnings	(928.68 M)
	Working Capital	358.65 M
	Net Asset	413.84 M

About Phathom Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Phathom Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phathom Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phathom Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC